Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09GSV
|
||||
| Former ID |
DIB009566
|
||||
| Drug Name |
FBT-A05
|
||||
| Synonyms |
Lymphomun; Bi-20; TPBs-05; Anti-CD20 bivalent monoclonal antibody (hematological cancer), Fresenius Biotech; Trifunctional antibody therapy (blood malignancy), Fresenius/Trion; Anti-CD20 bivalent monoclonal antibody (B-cell lymphoma, Triomab), Trion/Fresenius
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Chronic lymphocytic leukaemia [ICD10:C91] | Phase 1/2 | [548949] | ||
| Company |
TRION Pharma GmbH
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | [532416] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| Ref 532416 | Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013 Jul 2;11:160. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.